title: Lethal leukoencephalopathy secondary to Tegafur, a 5-fluorouracil prodrug.
authors.affiliation: Department of Pharmacology & Systems Therapeutics, Icahn School of Medicine, New York City, NY, United States. Electronic address: salvador.sierra@mssm.edu.
authors.forename: Salvador
authors.initials: S
authors.lastname: Sierra
authors.affiliation: Department of Medical Genomics, Royal Prince Alfred Hospital, Sydney, Australia.
authors.forename: Natasha
authors.initials: N
authors.lastname: Luquin
authors.affiliation: Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Carrato
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D017809:Fatal Outcome; D005472:Fluorouracil / Q000009:adverse effects*; D006801:Humans; D056784:Leukoencephalopathies / Q000139:chemically induced* / Q000175:diagnosis*; D008297:Male; D011355:Prodrugs / Q000009:adverse effects*; D005641:Tegafur / Q000009:adverse effects*
chemical_list: D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D005641:Tegafur; D005472:Fluorouracil
keywords: 5-Fluorouracil; Tegafur; Toxic leukoencephalopathy